|
|
|
| Effects of Saccharomyces Boulardii on Symptom Improvement and Serum Inflammatory Factors in Children with Acute Infectious Diarrhea |
| CHEN Dandan, YIN Yangyan, GUI Dongmei |
| The First Affiliated Hospital of Hainan Medical College, Hainan Haikou 570100, China |
|
|
|
|
Abstract Objective: To study the clinical efficacy of saccharomyces boulardii in the treatment of children with acute infectious diarrhea (AID), and to evaluate its effects on symptom improvement and serum inflammatory factors. Methods: 160 children patients with AID treated in our hospital from April 2017 to April 2019 were selected for the study, and the patients were divided into observation group (odd medical record numbers) and control group (even medical record numbers) using a odd-even number method, with 80 cases in each group. On the basis of routine measures, control group was administrated montmorillonite powder, and observation group was administrated saccharomyces boulardii combined with montmorillonite powder, and they were treated for one week. The effective rate of treatment, symptom improvement, stool frequency traits, intestinal microbial condition, levels of serum inflammatory indexes [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP), interferon-γ (INF-γ)] and occurrence of adverse reactions were compared between the two groups. Results: The effective rate of treatment in observation group was significantly higher than that in control group (92.50% vs 80.00%) (P<0.05). The disappearance times of abdominal pain, vomiting and diarrhea and hospital stay in observation group were significantly lower than those in control group (P<0.05). After treatment, the stool frequency, stool trait score, and levels of IL-6, TNF-α, hs-CRP and INF-γ in the two groups were significantly decreased compared with those before treatment, while the quantity of bacteroides was significantly increased (P<0.05), and the above indexes in observation group were significantly different from those in control group at the same time point (P<0.05). There was no significant difference in incidence rate of adverse reactions between the two groups during treatment (P>0.05). Conclusion: Saccharomyces boulardii has significant clinical efficacy in the treatment of acute infectious diarrhea, and it can effectively improve the symptoms, and reduce the inflammatory response, with good safety and good clinical application value.
|
|
|
|
|
|
[1] 孙立珍,孙立平,丁淑芹.北京地区感染性腹泻病原菌监测[J].热带医学杂志,2018,18(1):97~99.
[2] 刘瑛琦,王燕南,齐建新.肠炎宁胶囊治疗急性感染性腹泻100例临床观察[J].川北医学院学报,2018,33(1):53~55.
[3] 巩冬艳,周莉,张莉.小儿感染性腹泻流行病学特点及预防控制对策研究[J].护理实践与研究,2019,16(13):12~14.
[4] 诸福棠实用儿科学[M].第7版.北京:人民卫生出版社,2002.1286~1298.
[5] 蒋永悟.2016年至2018年陕西省安康市轮状病毒感染性腹泻检测结果分析[J].山西医药杂志,2019,48(1):98~100.
[6] 胡海贇,庄晓岚,马燕雅,等.微生态制剂防治儿童感染性腹泻的有效性评价[J].中国微生态学杂志,2019,31(5):577~580.
[7] 王丹,程义伍,周海群.布拉氏酵母菌联合蒙脱石散对小儿急性腹泻的疗效及T细胞亚群的影响[J].药物评价研究,2020,43(6):124~127.
[8] 胡蓉蓉.血清淀粉样蛋白A和高敏C反应蛋白在儿童腹泻中的应用[J].检验医学,2018,33(3):269~270.
[9] 邱慧明,熊斌,陈晓霞.布拉酵母菌治疗儿童感染性腹泻的效果及其对血清IL-8、IL-10及C反应蛋白水平的影响[J].儿科药学杂志,2018,24(4):29~31. |
|
|
|
2021, Vol. 27 
